Versartis Inc (VSAR) SVP Sells $26,122.60 in Stock

Versartis Inc (NASDAQ:VSAR) SVP Paul Westberg sold 1,316 shares of the business’s stock in a transaction on Wednesday, April 19th. The shares were sold at an average price of $19.85, for a total transaction of $26,122.60. Following the sale, the senior vice president now directly owns 68,228 shares of the company’s stock, valued at $1,354,325.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Paul Westberg also recently made the following trade(s):

  • On Monday, February 27th, Paul Westberg sold 12,500 shares of Versartis stock. The shares were sold at an average price of $22.50, for a total transaction of $281,250.00.
  • On Thursday, February 23rd, Paul Westberg sold 25,000 shares of Versartis stock. The shares were sold at an average price of $18.75, for a total transaction of $468,750.00.
  • On Monday, January 30th, Paul Westberg sold 1,916 shares of Versartis stock. The shares were sold at an average price of $13.85, for a total transaction of $26,536.60.

Shares of Versartis Inc (NASDAQ:VSAR) traded down 1.99% during mid-day trading on Thursday, reaching $19.70. 163,421 shares of the company were exchanged. Versartis Inc has a 12 month low of $7.05 and a 12 month high of $24.00. The firm’s 50-day moving average is $20.47 and its 200-day moving average is $15.56. The company’s market capitalization is $690.41 million.

Versartis (NASDAQ:VSAR) last posted its earnings results on Tuesday, February 21st. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by $0.02. During the same quarter last year, the business posted ($0.69) EPS. On average, equities analysts forecast that Versartis Inc will post ($2.51) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Versartis (NASDAQ:VSAR)

ILLEGAL ACTIVITY WARNING: “Versartis Inc (VSAR) SVP Sells $26,122.60 in Stock” was published by sleekmoney and is the sole property of of sleekmoney. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at http://sleekmoney.com/versartis-inc-vsar-svp-sells-26122-60-in-stock/1751431.html.

Several analysts have recently issued reports on VSAR shares. Zacks Investment Research cut shares of Versartis from a “buy” rating to a “hold” rating in a research note on Thursday, January 12th. Piper Jaffray Companies boosted their price objective on shares of Versartis from $22.00 to $26.00 and gave the company an “overweight” rating in a research note on Tuesday, April 4th. Barclays PLC started coverage on shares of Versartis in a research note on Thursday, March 9th. They set an “overweight” rating and a $28.00 price objective for the company. Finally, Canaccord Genuity reissued a “buy” rating and set a $28.00 price objective on shares of Versartis in a research note on Wednesday, February 22nd. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $23.86.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Wells Fargo & Company MN raised its position in Versartis by 107.4% in the third quarter. Wells Fargo & Company MN now owns 11,492 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 5,952 shares during the last quarter. Monashee Investment Management LLC bought a new stake in Versartis during the third quarter valued at about $1,838,000. NF Trinity Capital Hong Kong Ltd bought a new stake in Versartis during the third quarter valued at about $3,000,000. Spark Investment Management LLC bought a new stake in Versartis during the third quarter valued at about $199,000. Finally, Aisling Capital LLC raised its stake in Versartis by 10.7% in the third quarter. Aisling Capital LLC now owns 2,524,465 shares of the biopharmaceutical company’s stock valued at $30,925,000 after buying an additional 244,897 shares in the last quarter. Institutional investors and hedge funds own 70.15% of the company’s stock.

Versartis Company Profile

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

5 Day Chart for NASDAQ:VSAR

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/versartis-inc-vsar-svp-sells-26122-60-in-stock/1751431.html

Receive News & Ratings for Versartis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *